Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.
Recce Pharmaceuticals Ltd. has announced the granting of a crucial patent in China for its innovative synthetic anti-infectives, further extending its global patent protection until 2035. This development positions Recce to capitalize on China’s rapidly growing pharmaceutical market, the second-largest globally, which is supported by robust government backing for R&D. The patent covers key anti-infectives, RECCE 327 and RECCE 529, aimed at treating a wide array of human infections.
For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.
